叶酸联合维生素B12对非小细胞肺癌患者化疗疗效的影响

Effect of folic acid combined with vitamin B12 in chemotherapy of patients with non-small cell lung cancer

目的探讨叶酸联合维生素B12对非小细胞肺癌患者化疗效果的影响。方法选取2012年5月-2016年2月在郑州大学附属医院南阳医院接受化疗的非小细胞肺癌患者114例,依据随机数表法分为观察组(叶酸^+维生素B12^+化疗)和对照组(常规化疗),比较两组患者的临床疗效、ECOG评分、超敏C反应蛋白(hs-CRP)、癌胚抗原(CEA)、CD4^+/CD8^+及不良反应。结果观察组57例,完全缓解6例,部分缓解20例,稳定25例,进展6例,稳定率为89.47%,缓解率为45.61%;对照组完全缓解3例,部分缓解11例,稳定23例,进展20例,稳定率为64.91%,缓解率为24.56%,两组患者的稳定率和缓解率比较,差异有统计学意义(P<0.05)。两组ECOG评分比较,差异有统计学意义(P<0.05)。治疗前,两组患者的hs-CRP、CEA及CD4^+/CD8^+比较,差异无统计学意义(P>0.05)。治疗结束后,两组患者的hs-CRP、CEA及CD4^+/CD8^+比较,差异有统计学意义(P<0.05),两组患者的不良反应发生率比较,差异有统计学意义(P<0.05)。结论叶酸联合维生素B12能有效提高非小细胞肺癌患者化疗效果,改善患者免疫功能及血液学指标,降低不良反应发生率。

Objective To investigate the effect of folic acid and vitamin B12on the efficacy of chemotherapy in patients with non-small cell lung cancer.Methods A total of114patients with non-small cell lung cancer who received chemotherapy in our hospital from May2012to February2016were selected,and divided into observation group(folic acid and vitamin B12+chemotherapy)and control group(conventional chemotherapy)according to the random table method.The clinical curative effect,ECOG score,high-sensitivity C-reactive protein(hs-CRP),carcinoembryonic antigen(CEA),CD4+/CD8+and adverse reactions were compared between the two groups.Results In the57cases of the observation group,6cases had complete remission,20cases had partial remission,25cases were stable,and6cases progressed,the stability rate was89.47%,the remission rate was45.61%;in the control group,3cases completely relieved,11cases partially relieved,23cases were stable,and20cases had disease progression,the stability rate was64.91%and the remission rate was24.56%.The stability and remission rates of the two groups were statistically different between the two groups(P<0.05).The ECOG scores of the two groups were statistically different(P<0.05).There was no significant difference in hs-CRP,CEA or CD4+/CD8+between the two groups before treatment(P>0.05).After treatment,the levels of hs-CRP,CEA and CD4+/CD8+in the two groups were significantly different(P<0.05).The incidences of adverse reactions in the two groups were statistically different(P<0.05).Conclusions Folic acid combined with vitamin B12can effectively improve the effect of chemotherapy in patients with non-small cell lung cancer,improve the immune function and hematological parameters,and reduce the incidences of adverse reactions.